

CURRICULUM VITAE

August 2011

Name: Becky Ann Briesacher

Education:

1986	B.A.	Art History, University of California, Berkeley
1988	M.A.	Humanities, Williams College, Massachusetts
2001	Ph.D.	Pharmaceutical Health Services Research, University of Maryland, Baltimore

Academic Appointments:

11/2002–2004	Assistant Research Professor, University of Maryland, School of Pharmacy (non–tenure track position), Department of Pharmaceutical Health Services Research, Baltimore, MD
3/2004 –2/2009	Assistant Professor of Medicine, University of Massachusetts Medical School (tenure track position), Department of Medicine, Division of Geriatric Medicine, Worcester, MA
2005 –	Associate/Assistant Professor of Medicine, Graduate School Biomedical Sciences, Clinical and Population Health Research, University of Massachusetts Medical School, Worcester, MA
3/2009–	Associate Professor of Medicine, University of Massachusetts Medical School (tenure track position), Department of Medicine, Division of Geriatric Medicine, Worcester, MA

Other Professional Positions:

1991–1995	Manager/Editorial Associate, Institute for Pharmaceutical Economics, University of the Sciences in Philadelphia (PCPS), Philadelphia, PA
1992–1997	Senior Associate, Technology Assessment and Pharmacoeconomics Services, Ben Franklin Center of Excellence, University of the Sciences in Philadelphia (PCPS), Philadelphia, PA
1994–1997	Director and Chair, Marvin Samson Center for the History of Pharmacy, University of the Sciences in Philadelphia (PCPS), Philadelphia, PA
1995–1997	Director, Institute for Pharmaceutical Economics, University of the Sciences in Philadelphia (PCPS), Philadelphia, PA
2001–2004	Director of Research, Peter Lamy Center on Drug Therapy and Aging, University of Maryland, School of Pharmacy, Baltimore, MD

Service Activities:

Committee Assignments, University of Massachusetts Medical School

2005–2009	Admissions Committee, Clinical and Population Health Research
2007–	Curriculum Committee, Clinical and Population Health Research
2008–	UMMS representative, Gerontology Advisory Board, Colleges of Worcester Consortium
2008–	Program Director, Massachusetts College of Pharmacy and Health Sciences Fellowship
2010–	Antipsychotic Task Force, Bureau of Health Care Safety and Quality, Massachusetts Department of Public Health

Committee Assignments, National

2007–	Reviewer, Changes in Health Care Financing and Organization (HCFO) Initiative, Robert Wood Johnson Foundation
2008–	Workgroup member, AHRQ DEcIDE Research Network, Working Paper Series on “Good Research Practice”
2010–	Reviewer, Health Systems Research study section, Agency for Healthcare Research and Quality

Committee Assignments, International

5/2010	Consensus Panel on Indicators of Prescribing Quality in Long-Term Care, Institute for Clinical Evaluative Sciences, Toronto, Canada
--------	---

Membership in Professional Societies:

1995– 2009	AcademyHealth
1998–	International Health Economics Association
1996–2000	International Society of Pharmaceutical Outcome Research
2002–	Gerontological Society of America
2009–	American Society of Health Economists

Reviewer:

2001–2005	American Journal of Geriatric Pharmacotherapy
2001–	American Journal of Managed Care
2007–	Archives of General Psychiatry
2002–	Archives of Internal Medicine
2003–	Arthritis Care Research and Review
2001–	Clinical Therapeutics
2001–	Health Affairs
2001–	Health Care Financing Review
2001–2004	Health Economics
2006–	Inquiry
2006–	Journal of Aging and Health
2005–	Journal of Health Care for the Poor and Underserved
2001–	Journal of the American Geriatrics Society
2007–	JAMA
2004–	Medical Care
2008–	Social Science & Medicine

Awards and Honors:

1986–88	Williams College, Graduate Fellowship
1997	University of Maryland, Graduate Merit Award
1999	American Foundation for Pharmaceutical Education Pre-doctoral Fellowship
2000	AcademyHealth, Best Paper
2001	Health Care Financing Administration, Dissertation Fellowship
2003	MEDSTAT, MarketScan Investigator’s Award
2004	ISPOR, Award of Distinction
2004	National Institute on Aging, Summer Institute Fellow

2005	American Geriatrics Society, Comorbid Disease and Multiple Morbidity in an Aging Society Fellow
2007	State-of-the Art and Ollie Randall Symposium Award, Gerontological Society of America
2006–2008	Medical Care, Exceptional Reviewer
2008	The Brookdale Foundation, Leadership in Aging Fellowship Finalist
2009	AAMC Mid-Career Women Faculty Professional Development Seminar Invitee

Research Funding:*Completed*

2001–2002	Health Care Financing Administration Dissertation Fellowship Grant: Prescription-Filling Problems in the Medicare Population	(Principal Investigator)
2001–2002	Centers for Medicare and Medicare Services Identifying Comparative Datasets for the UMW Health and Retirement Fund Demonstration.	(Co-Investigator)
2001–2002	Omnicare, Inc Evaluation of Fracture Risk in a Skilled Nursing Facility Population.	(Co-Investigator)
2001–2002	US DHHS, Office of Disability, Aging, and Long-term Care. Contract No. HHS-100-01-0023 Utilization and Access to Prescription Drugs for People with Disabilities.	(Co-Investigator)
2001–2002	Novartis Pharmaceuticals Corporation The Influence of Benefit Design Features on Drug Selection Decisions and Spending.	(Co-Investigator)
2001–2003	The Commonwealth Fund Addressing the Costs and Quality of Prescription Coverage of Medicare Beneficiaries.	(Co-Investigator)
2002	Centers for Medicare and Medicaid Services Prescription Drug Use among Institutionalized Medicare Beneficiaries	(Co-Investigator)
2002	Novartis Pharmaceuticals Corporation The Influence of Tiered Copays on Prescription and Medical Spending.	(Principal Investigator)
2002–2003	Novartis Pharmaceuticals Corporation What Effect Do Tiered Drug Plans Have on NSAID Use?	(Principal Investigator)
2002–2003	Johns Hopkins University/Kaiser Family Foundation Racial and Ethnic Disparities in Prescription Drug Expenditures and Use By Medicare Beneficiaries with Chronic Conditions.	(Co-Investigator)
2002–2003	Centers for Medicare and Medicaid Services Evaluation of Drug Therapy Guidelines to Reduce the Use of Potentially Inappropriate Drug Use in Nursing Homes.	(Principal Investigator)

2003	US DHHS Substance Abuse and Mental Health Administration Frequency of Potentially Problematic Drug Use in Elders.	(Co-Investigator)
2002–2003	Centers for Medicare and Medicaid Services Contract No. 500-00-032 The Impact of Prescription Drug Coverage on Medicare Program Expenditures: A Case Study of the Evaluation of the United Mine Workers' Demonstration.	(Co-Investigator)
2003	Novartis Pharmaceuticals Corporation Do Self-Assessments of Health Status Predict Hospitalization in Patients with Heart Failure?	(Principal Investigator)
2004	Novartis Pharmaceuticals Corporation Resource Utilization of Paget's Disease.	(Principal Investigator)
2003–2005	The Commonwealth Fund Evaluation of the Effect of Medicare Drug Policy Decisions on Vulnerable Seniors.	(Principal Investigator)
2003–2004	The Robert Wood Johnson Foundation Establishing the Value of Stable Prescription Coverage for Medicare Beneficiaries.	(Co-Investigator)
2004	AARP Methodological Issues in Estimating Drug Coverage with the Medicare Current Beneficiary Survey.	(Principal Investigator)
2003–2004	Centers for Medicare and Medicaid Services Trends in Antipsychotic Use and other Problematic Drugs in Long-term Care Facilities.	(Principal Investigator)
2004–2005	Commonwealth Medicine Antipsychotic Use in Massachusetts Medicaid Population.	(Principal Investigator)
2004–2005	The Kaiser Family Foundation Health Care and Discretionary Income.	(Co-Investigator)
2005–2006	Novartis Pharmaceuticals Corporation The Impact of Adherence with Bisphosphonates on Costs.	(Principal Investigator)
2006–2008	Novartis Pharmaceuticals Corporation A Comparison of Medication Adherence Rates across Multiple Chronic Conditions.	(Principal Investigator)
2006–2007	The Commonwealth Fund Follow up Study of Discretionary Income and Medication Costs.	(Co-Investigator)
2006–2008	State of Oregon Attorney General Consumer and Prescribed Education Grant, The Marketing of Medicines.	(Co-Investigator)
2008	Commonwealth Medicine Pay-for-Performance in Nursing Homes.	(Co-Investigator)

2007–2009	The Robert Wood Johnson Foundation Changes in Health Care Financing and Organization (HCFO) Evaluation of Medicare Part D in Nursing Homes.	(Principal Investigator)
2007–2009	Novartis Pharmaceuticals Corporation The Impact of Dosing Schedule on Adherence with Bisphosphonates.	(Principal Investigator)
2006–2011	NIH-National Institute on Aging (R01AG028745) Evaluation of Medicare Part D and Cost-related Underuse of Medications.	(Co-Investigator)
<i>Ongoing</i>		
2008–2013	NIH-National Institute on Aging Research Scientist Development Award (K01AG031836) Cost-related Nonadherence and the Health of Older Adults.	(Principal Investigator)
2010–2011	NIH-National Institute on Aging Administrative Supplement (NOT-OD-09-056) Cost-related Nonadherence and the Health of Older Adults.	(Principal Investigator)
2010–2013	Agency for Healthcare Research and Quality (AHRQ) (R18HS019351-01) iADAPT: Off-Label Use of Antipsychotics in the Nursing Home	(Co-Investigator)
2011–2014	NIH-NIA/Subcontract with National Bureau of Economic Research (1P01AG031098-01A1) Expanding the National Health Accounts	(Co-Investigator)
2010–2012	Agency for Healthcare Research and Quality (AHRQ) (R21 HS19579-01) Optimizing Chronic Disease Prevention and Management in Advanced Dementia	(Co-Investigator)

Teaching:*Teaching Activities, University of Massachusetts Medical School*

2006–present	Epidemiology and Research Methods (CTS 602A & 602B) Clinical and Population Health Research Lecturer 6-8 graduate students 2 hour lecture
2007–2009	Epidemiology and Biostatistics (PPS2) Department of Family Medicine and Community Health Small Group Leader 10-14 medical students 2 hours/week for 6 weeks
2005–present	Health Policy and the Practice of Medicine Interclerkship Office of Medical Education

	Small Group Leader 10-14 medical students 1 day seminar
2008–present	Advanced Analytic Methods in Health Outcomes Research (CTS 716) Clinical and Population Health Research PhD Program Course Master 5 graduate students 4 hours/week for 3 months
2009–present	Evidence Based Medicine Conference Department of Medicine, Division of Geriatric Medicine Faculty Preceptor 2-3 residents 1 day seminar
2010–present	Design of Observational Studies and Clinical Trials Clinical Investigation Lecturer 6-8 graduate students 2 hour lecture
2010-present	Geriatric Medicine Fellowship 1 post-doctoral student 2 hour directed study

Other Teaching Activities

1995–1997	Lecturer, Health Policy Forum, Thomas Jefferson University Hospital, Philadelphia, PA
1995–1996	Lecturer, Pharmacy Systems Management, Philadelphia College of Pharmacy and Science, Philadelphia, PA
2000	Lecturer, Study Design and Analysis, University of Maryland, School of Pharmacy, Baltimore, MD
2003	Lecturer, Economics of Aging , University of Maryland, Baltimore, MD
2003	Lecturer, Pharmacy and Aging, University of Maryland, Baltimore, MD
2003	Lecturer, Health Care for Aging Population, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD
2002–2004	Lecturer, Advanced Research Methods, University of Maryland, Baltimore, MD

Mentoring/Advising Activities, University of Massachusetts Medical School

Thesis Research Advisory Committee

2007–2010	Yat (Gary) Leung, Clinical and Population Health Research
2009–	Yendelela Cuffee, Clinical and Population Health Research

Thesis Mentor

2009– Yong Chen, Clinical and Population Health Research

Qualifying Exam Committee

2011– Eric Smith, Millennium PhD program

Faculty

2006– Jennifer Tjia, MD, MS, Division of Geriatric Medicine
 2008– Leslie Harrold, MD, MPH, Department of Rheumatology
 2011– Jane Saczynski, PhD, Division of Geriatric Medicine

Resident

2008 Ailis Clyne, MD, MS, Preventive Medicine Resident, Department of Family Medicine and Community Health

Other Mentoring/Advising Activities

Graduate Students

2001–2004 Puneet Singhal, PhD, Department of Pharmaceutical Health Services Research, University of Maryland
 2001–2003 Jalpa Doshi, PhD, Department of Pharmaceutical Health Services Research, University of Maryland
 2001–2002 Sachin Kamal-Bahl, PhD, Department of Pharmaceutical Health Services Research, University of Maryland

Postdoctoral Fellows

2003–2004 Juliette Taylor Toure, Geriatric Pharmacotherapy Residency, University of Maryland

Thesis Advisory Committee

2001–2005 M. Rhona Limcangco, Department of Pharmaceutical Health Services Research, University of Maryland

Invited Presentations:

Presentations, University of Massachusetts Medical School

2006 Health Policy Partnership, Commonwealth Medicine
 2006 Medical Grand Rounds, St. Vincent Hospital
 2006–2007 Academic Conference, Commonwealth Medicine
 2007–2008 Rosalie Wolf Interdisciplinary Geriatric Health Care Research Center Seminar Series, Division of Geriatric Medicine

- 2009 Research into Practice and Policy Discussion Forum, Center for Health Care Policy and Research, Commonwealth Medicine

Other Presentations

- 2006 Invited lecturer, Pharmaceutical Policy Research Seminar, Harvard Medical School, Boston, MA
- 2007 Invited discussant, Centers for Medicare and Medicaid Services, Distributing Medicare Part D Data to Research Community, Baltimore, MD
- 2008 Invited discussant, Brown University, Off-Label Antipsychotic Use in Nursing Homes, Providence, RI
- 2011 Invited lecturer, Health Services Research Colloquium, Medicare Part D in Long-term Care, Penn State University

Bibliography:

Articles in Peer Reviewed Journals

1. Lewis NJ. Patwell JT. Briesacher BA. The role of insurance claims databases in drug therapy outcomes research. *Pharmacoeconomics*. 4(5):323-30, 1993 Nov.
2. Wertheimer AI. Briesacher BA. Specialization in pharmacy: the United States experience, *International Pharmacy Journal* 1994;8:116-119.
3. McGhan WF. Briesacher BA. Implementing pharmacoeconomic outcomes management. *Pharmacoeconomics*. 6(5):412-6, 1994 Nov.
4. Briesacher B. DuChane J. Drug utilization review in the managed care environment. *Medical Interface*. 8(3):72-4, 76-8, 1995 Mar.
5. Briesacher BA. Erwin WG. Cornwell S. Claims Database Research. *American Druggist*. 48-55, 1995 April.
6. Erwin WG. Briesacher BA. Franic D. Management Overview of Chronic Nonmalignant Pain in Long Term Care, *The Consultant Pharmacist* 1995;10:1034-1049.
7. Briesacher B. Erwin WG. Managed care organizations: the new research partners. *Medical Interface*. 8(12):68-73, 77, 1995 Dec.
8. Briesacher B. Corey R. Patient satisfaction with pharmaceutical services at independent and chain pharmacies. *American Journal of Health-System Pharmacy*. 54(5):531-6, 1997 Mar 1.
9. Baran RW. Keil DP. Patterson HK. Doyle J. Briesacher BA. Erwin WG. Diagnosis and Treatment of Osteoporosis in Long-Term Care Facilities. *The Consultant Pharmacist*. 1998;13(6): 685-699.
10. Stuart B. Briesacher BA. Ahern F. Kidder D. Zacker C. Erwin G. Gilden D. Fahlman C. Drug use and prescribing problems in four state Medicaid programs. *Health Care Financing Review*. 20(3):63-78, 1999.
11. Briesacher BA. Stuart B. Peluso R. Drug use and prescribing problems in the community dwelling elderly: a study of three state Medicaid programs. *Clinical Therapeutics*. 21(12):2156-72, 1999 Dec.

12. Stuart B. Shea D. Briesacher B. Dynamics in drug coverage of Medicare beneficiaries: finders, losers, switchers. *Health Affairs*. 20(2):86-99, 2001 Mar-Apr.
13. Stuart B. Briesacher B. Medication decisions--right and wrong. *Medical Care Research & Review*. 59(2):123-45, 2002 Jun.
14. Stuart B. Singhal PK. Fahlman C. Doshi J. Briesacher B. Employer-sponsored health insurance and prescription drug coverage for new retirees: dramatic declines in five years. *Health Affairs. Suppl Web Exclusives*:W3-334-41, 2003 Jul-Dec.
15. Kamal-Bahl SJ. Doshi JA. Stuart BC. Briesacher BA. Propoxyphene use by community-dwelling and institutionalized elderly Medicare beneficiaries. *Journal of the American Geriatrics Society*. 51(8):1099-104, 2003 Aug.
16. Stuart B. Kamal-Bahl S. Briesacher B. Lee E. Doshi J. Zuckerman IH. Verovsky I. Beers MH. Erwin G. Friedley N. Trends in the prescription of inappropriate drugs for the elderly between 1995 and 1999. *American Journal Geriatric Pharmacotherapy*. 1(2):61-74, 2003 Dec.
17. Kamal-Bahl S. Briesacher B. How do incentive-based formularies influence drug selection and spending for hypertension? *Health Affairs*. 23(1):227-36, 2004 Jan-Feb.
18. Wrobel MV. Doshi J. Stuart BC. Briesacher B. Predictability of prescription drug expenditures for Medicare beneficiaries. *Health Care Financing Review*. 25(2):37-46, Winter 2003-2004.
19. Shea DG. Stuart BC. Briesacher B. Participation and crowd-out in a Medicare drug benefit: simulation estimates. *Health Care Financing Review*. 25(2):47-61, Winter 2003-2004.
20. Briesacher B. Limcangco R. Gaskin D. Racial and ethnic disparities in prescription coverage and medication use. *Health Care Financing Review*. 25(2):63-76, Winter 2003-2004.
21. Briesacher B. Kamal-Bahl S. Hochberg M. Orwig D. Kahler KH. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. *Archives of Internal Medicine*. 164(15):1679-84, 2004 Aug 9-23.
22. Stuart B. Doshi JA. Briesacher BA. Wrobel MV, Baysac F. Impact of prescription coverage on hospital and physician costs: a case study of Medicare beneficiaries with chronic obstructive pulmonary disease. *Clinical Therapeutics* 2004; 26(10):1688-99.
23. Doshi JA. Shaffer T. Briesacher B. National estimates of medication use in nursing homes: Findings from the 1997 Medicare Current Beneficiary Survey and the 1996 Medical Expenditure Survey. *Journal of the American Geriatrics Society* 2005;53(3):438-443
24. Briesacher B. Limcangco R. Simoni-Wastila L. Doshi J. Gurwitz J. Evaluation of nationally mandated drug use reviews to improve patient safety in nursing homes: a natural experiment. *Journal of the American Geriatrics Society* 2005;53(6):991-996.
25. Stuart B. Briesacher B. Shea DG. Cooper B. Baysac FS. Limcangco MR. Riding the rollercoaster: the ups and downs in out-of-pocket spending under the standard Medicare drug benefit. *Health Affairs* 2005; 24(4):1-10, Jul-Aug.

26. Simoni-Wastila L. Zuckerman I. Singhal P. Briesacher BA. Hsu V. National estimates of exposure to prescription drugs with addiction potential in community-dwelling elders. *Substance Abuse* 2005;26(1):33-42.
27. Briesacher B. Stuart B. Doshi J. Wrobel MV. Medicare beneficiaries and the impact of gaining prescription drug coverage on inpatient and physician spending. *Health Services Research* 2005; 40(5):1279-1296
28. Briesacher BA. Limcangco MR. Simoni-Wastila L. Doshi JA. Levins SR. Shea DG. Stuart B. The quality of antipsychotic prescribing in nursing homes. *Archives of Internal Medicine* 2005;165(11) 1280-1285.
29. Briesacher BA. Orwig D. Seton M. Omar M. Kahler K. Medical care costs of Paget's disease of bone in a privately-insured population. *Bone* 2005;37(6).
30. Toure J. Brandt N. Limcangco MR. Briesacher BA. Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted living facilities. *American Journal of Geriatric Pharmacotherapy* 2006; 4(1) 25-35.
31. Gaskin DJ. Briesacher B. Limcangco L. Brigantti L. Lillie-Blanton M. Exploring racial and ethnic disparities in prescription drug spending and use of among Medicare beneficiaries, *American Journal of Geriatric Pharmacotherapy* 2006;4(2) 1-17.
32. Kirking DM. Lee JA. Ellis J. Briesacher B. McKercher P. Patient-reported underuse of prescription medications: A comparison of nine surveys. *Medical Care Research and Review* 2006;63(4) 427-446.
33. Briesacher B. Andrade S. Kahler KH. Yood RA. Economic impact of the previous year's adherence with bisphosphonates. *Arthritis Rheum* 2006;54:S85-S86.
34. Shea DG. Terza JV. Briesacher BA. Stuart B. Moral hazard in Medicare coverage for prescription drugs. *Health Services Research* 2007; 42(3) 933-949.
35. Stuart B. Wrobel M. Doshi JA. Briesacher BA. Will Part D produce savings in Part A and Part B? *Inquiry* 2007: Vol. 44, No. 2, pp. 146-156.
36. Field TS. Mazor K. Debellis K. Briesacher BA. Gurwitz JH. Adverse drug events resulting from patient errors among older adults. *Journal of the American Geriatrics Society* 2007;55(2)271-276.
37. Briesacher BA. Andrade SE. Yood RA. Kahler KH. Consequences of poor compliance with bisphosphonates. *Bone* 2007 Jul 18.
38. Briesacher BA. Gurwitz JH. Soumerai SB. Patients at-risk for cost-related medication nonadherence: A review of the literature. *Journal of General Internal Medicine* 2007;22(6):864-71.
39. Briesacher BA. Andrade SE. Fouayzi H. Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. *Pharmacotherapy* 2008;28:437-43.
40. Briesacher BA. Field TS. Baril J. Gurwitz JH. Can pay-for-performance take nursing home care to the next level? *Journal of the American Geriatrics Society* 2008. 56(10):1937-9.

41. Madden JM. Graves AJ. Zhang F. Adams AS. Briesacher BA. Ross-Degnan D. Gurwitz JH. Pierre-Jacques M. Safran DG. Adler GS. Soumerai SB. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. *JAMA* 2008. 99(16):1922-1928.
42. Briesacher BA. Ross-Degnan D. Adams AS. Wagner AK. Gurwitz JH. Soumerai SB. A new measure of medication affordability. *Social Work in Public Health* 2009. 24(6):600-612.
43. Tjia J. Briesacher BA. Soumerai SB. Pierre-Jacques M. Zhang F. Ross-Degnan D. Gurwitz JH. Medicare beneficiaries and free prescription drug samples: a national survey. *Journal of General Internal Medicine* 2008. 23(6):709-14.
44. Lau DT. Briesacher BA. Mercaldo ND. Halpern L. Osterberg EC. Jarzebowski M. McKoy JM. Mazor K. Older patients' perceptions of medication importance and worth: an exploratory pilot study. *Drugs & Aging*. 25(12):1061-75, 2008.
45. Tjia J. Briesacher BA. Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus. *Journal of the American Geriatrics Society* 2008. 56(10):1879-86.
46. Harrold LR. Andrade SE. Briesacher BA. Raebel MA. Fouayzi H. Yood RA. Ockene IS. Adherence with urate-lowering therapies for the treatment of gout. *Arthritis Research & Therapy* 2009. 11(2):R46.
47. Madden JM. Graves AJ. Ross-Degnan D. Briesacher BA. Soumerai SB. Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. *JAMA* 2009;99(16):1922-1928.
48. Briesacher BA. Field TS. Baril J. Gurwitz JH. Pay-for-performance in nursing homes. *Health Care Financing Review* 2009. 30(3):1-13.
49. Briesacher BA. Andrade SE. Fouayzi H. Chan KA. Medication adherence and use of generic drug therapies. *American Journal of Managed Care* 2009. 15(7):450-6.
50. Tjia J. Bonner A. Briesacher BA. McGee S. Terrill E. Miller K. Medication discrepancies upon hospital to skilled nursing facility transitions. *Journal of General Internal Medicine* 2009. 24(5):630-5.
51. Briesacher BA. Soumerai SB. Field TS. Fouayzi H. Gurwitz JH. Nursing home residents and enrollment in Medicare Part D. *Journal of the American Geriatrics Society* 2009. 57(10):1902-7.
52. Briesacher BA. Andrade SE. Harrold LR. Fouayzi H. Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. *American Journal of Medicine* 2010. 123(3):275-80.
53. Harrold LR. Andrade SE. Briesacher BA. Raebel MA. Fouayzi H. Yood RA. Ockene IS. The dynamics of chronic gout treatment: medication gaps and return to therapy. *American Journal of Medicine* 2010. 123(1):54-9.

54. Tjia J, Briesacher B, Xie D, Fu J, Goldberg RJ. Disparities in combination drug therapy use in older adults with coronary heart disease: a cross-sectional time-series in a nationally representative US sample. *Drugs & Aging* 2010. 27(2):149-58.
55. Chen Y, Briesacher BA, Field TS, Tjia J, Lau D, Gurwitz JH. Unexplained variation across U.S. nursing homes in antipsychotic prescribing rates. *Archives of Internal Medicine* 2010. 170(1):89-95.
56. Briesacher BA, Soumerai SB, Field TS, Fouayzi H, Gurwitz JH. Medicare part D's exclusion of benzodiazepines and fracture risk in nursing homes. *Archives of Internal Medicine* 2010. 170(8):693-8.
57. Briesacher BA, Ross-Degnan D, Wagner, AK, Fouayzi H, Zhang F, Gurwitz JH, Soumerai S. Out-of-pocket burden of health care spending and the adequacy of the Medicare Part D low-income subsidy. *Medical Care* 2010. 48(6):503-9, 2010.
58. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA Adherence and occurrence of fractures after switching to once-monthly oral bisphosphonates. *Pharmacoepidemiology and Drug Safety* 2010. 19(12):1233-40.
59. Chen Y, Briesacher BA. Use of instrumental variable in prescription drug research with observational data: A systematic review. *Journal of Clinical Epidemiology* 2011. 64(6):687-700.
60. Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. *BMC Pulmonary Medicine* 2011, 11:5.
61. Briesacher BA, Madden JM, Soumerai SB. Caution in generalizing part d results to medicare population. *Archives of Internal Medicine* 2011. 171(4):366-7.
62. Briesacher BA, Zhao Y, Madden JM, Zhang F, Adams AS, Tjia J, Ross-Degnan D, Gurwitz JH, Soumerai SB. Medicare part d and changes in prescription drug use and cost burden: national estimates for the medicare population, 2000-2007. *Medical Care* (in press).
63. Parsons C, Briesacher BA, Givens J, Chen Y, Tjia J. Intensity of cholinesterase inhibitor and memantine use in nursing home residents with advanced dementia. *Journal of the American Geriatrics Society*. 59(7):1253-9.
64. Briesacher BA, Quittner AL, Fouayzi H, Zhang J, Swensen A. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007. *Pediatric Pulmonology*. 46(8):770-6, 2011.

Ph.D. Dissertation

Briesacher B. *Reports of Unfilled Prescriptions in the Medicare Population*. University of Maryland, December 2001.

Book Chapters

1. Goppold B, Briesacher BA. Evaluating Pharmaceutical Costs and Outcomes in Managed Care. In: *The Role of Pharmacoeconomics in Outcomes Management*. Ed. N. Johnson and D. Nash. American Hospital Publishing, Inc., 1996.

2. Wertheimer AI, Dickson M, Briesacher BA. Pharmaceuticals in the health care system. In: *Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs*. Ed. Davis, P. Oxford Press, 1996.

Government Reports (selected):

1. Wamboldt P, Briesacher B, Stuart B, Kerney D, Rabatin V, and Doyle J. *An Evaluation of the Impact of Retrospective Drug Utilization Review for Antidepressant Medications in the Pennsylvania Medicaid Program*. Report for Commonwealth of Pennsylvania, An Evaluation of the Pennsylvania Medicaid Program Using a Public-Corporate Partnership, 1997.
2. Stuart B, Brandt N, Briesacher B, Fahlman C, Mullins D, Palumbo F, Pizarro J, Stuart L. *Prescription Costs for Medicare Beneficiaries: What We Know and What We Need to Know*. Final Report to US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation under contract No. SA-00-0064, February 2000.
3. Shea D, Stuart B, Briesacher B. *The Impact of Competition in the Medicare+Choice Market on Prescription Coverage of Medicare Beneficiaries*. Report for US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation under contract No. 52-6002036, March 2001.
4. Stuart B, Shea D, Briesacher B. *Trends in Prescription Drug Coverage of Medicare Beneficiaries, 1993-1997*, Report to US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation under contract No. 52-6002036, May 15, 2001.
5. Briesacher B, Doshi J, Stuart B, Zuckerman I. *Medication Use in Long-term Care Facilities and Community Settings for Medicare Beneficiaries with Cardiovascular Disease*. Report to US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Office of Disability, Aging, and Long-term Care Policy under contract No. HHS-100-01-0023, <http://aspe.hhs.gov/daltcp/reports/cdmeduse.htm>.
6. Briesacher B, Stuart B, Doshi J. *Medication Use by Medicare Beneficiaries Living in Nursing Homes and Assisted Living Facilities*. Report to US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Office of Disability, Aging, and Long-term Care Policy under contract No. HHS-100-01-0023, <http://aspe.hhs.gov/daltcp/reports/meduse.htm> June 2002.
7. Shea D, Stuart B, Briesacher B, Doshi J. *The Graying of Medicare's Disabled Population*. Report to US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Office of Disability, Aging, and Long-term Care Policy under contract No. HHS-100-01-0023, <http://aspe.hhs.gov/daltcp/reports/graying.htm>, March 2002.
8. Gaskin D, Briesacher B. How do patterns of prescription drug coverage and use differ for White, African American, and Latino Medicare beneficiaries under 65 and 65+, Chartpack, Report to The Henry J. Kaiser Family Foundation, <http://www.kff.org/content/2003/6098/> July 2003.
9. Wrobel M, Doshi JA, Stuart B, Briesacher B. *Predicting Drug Expenditures for Medicare Beneficiaries*. Report to the Centers for Medicare and Medicaid Services, under contract No. 500-00-032/TO# 4, July 2003.

10. Lambrew J, Briesacher B. *Medicare Prescription Drug Legislation: What It Means for Rural Beneficiaries*. Report to Center for American Progress, Washington DC: September 2003.
<http://www.gwhealthpolicy.org/downloads/ruralreport.pdf>
11. Stuart B, Briesacher B, Doshi JA, Wrobel M. *Impact of Prescription Drug Benefits on Medicare Program Expenditures*. Report to the Centers for Medicare and Medicaid Services, under contract No. 500-00-032/TO# 4, September 2003.
12. Briesacher B, Limcangco R, Simoni-Wastila L, Doshi J, Gurwitz, J. *Evaluation of Drug Therapy Guidelines to Reduce the Use of Potentially Inappropriate Drug Use in Nursing Homes*. Report to Centers for Medicare and Medicaid Services, Division of Nursing Homes, October 9, 2003.
13. Briesacher B, Limcangco R, Simoni-Wastila L, Doshi J. *Trends in Use of Antipsychotics in Long-term Care Facilities*. Report to Centers for Medicare and Medicaid Services, Division of Nursing Homes, June, 2004.

Presentations at National and International Meetings (selected):

- 1999 *Prescription Drug Costs for Medicare Beneficiaries: Coverage and Health Status Matter*. American Public Health Association, Chicago, IL.
- 2000 *Medication Decisions-Right and Wrong*. Conference on Pharmaceutical Costs and Pricing Practices, US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Washington DC.
- 2000 *Dynamics of Prescription Drug Coverage of Medicare Beneficiaries*. Academy for Health Services Research, Los Angeles, CA, (best paper presentation).
- 2001 *It's Time. Targeting Inappropriate Medications of the Elderly*, National Council on Patient Information and Education, Washington, DC.
- 2001 *Effects of Prescription Coverage on Reports of Unfilled Prescriptions*. International Health Economics Association, York, UK.
- 2001 *New Evidence on the Impact of Insurance on Use of Prescription Drugs by Medicare Beneficiaries*, International Health Economics Association, York, UK.
- 2002 Examining the Substitution Effects of Prescription Coverage on the Use of Medicare Part A and B Services: Assessment of Possible Sources of Data on Potential Comparison Groups, *Expert Meeting on Issue Associates with Evaluating the Medicare-UMWA Waiver Demonstration*, Co-sponsored by ASPE and CMS, Washington DC.
- 2002 Patterns in Prescription Coverage, Use, and Cost for Medicare Beneficiaries in 1999, *Medicare Prescription Drugs: Options and Possibilities*, Commonwealth Fund Roundtable, Washington DC.
- 2002 *Reports of Unfilled Prescriptions in the Medicare Population: Does Having Prescription Coverage Matter*, University of Michigan, Ann Arbor, MI.
- 2002 *Propoxyphene Use in the Elderly: Prevalence and Predictors of Use of a Potentially Inappropriate Drug*. Academy for Health Services Research, Washington, DC.

- 2002 *Participating and Crowd-Out in a Medicare Prescription Drug Benefit: Estimates from a Simulation.* Academy for Health Services Research and Health Policy, Washington DC.
- 2002 *Prescription Drug Coverage among the Medicare Disabled: Does Availability of Drug Coverage make a Difference?* Academy for Health Services Research and Health Policy, Washington DC.
- 2002 *Trends in Prescription Drug Coverage, Use and Cost for Medicare Beneficiaries (1993-1999).* Academy for Health Services Research, Washington, DC.
- 2002 *Reports of Unfilled Prescriptions in the Medicare Population: Does Having Prescription Coverage Matter?* Academy for Health Services Research, Washington, DC.
- 2002 *New Evidence on Use of Potentially Harmful Medications among Elderly Medicare Beneficiaries.* International Conference on Pharmacoepidemiology, Edinburgh, Scotland.
- 2002 *Prescription Drug Use among Older Adults.* American Public Health Association, podium presentation, Philadelphia, PA.
- 2002 *What Effect Do Tiered Drug Plans Have on NSAID Use?* American College of Rheumatology, podium presentation, New Orleans, LA.
- 2003 *Reports of Unfilled Prescriptions in the Medicare Population,* University of Michigan's Pharmaceutical Policy Summit, invited speaker, Washington, DC.
- 2003 *Changes in Functional Disability Levels and Medical Expenditures among Elderly Persons.* ISPOR, podium presentation, Arlington, VA.
- 2003 *Economic Effects of Benefit Design and Behavioral Parameters on Participation and Crowd-out in a Medicare Prescription Drug Benefit.* International Health Economics Association, podium presentation, San Francisco, CA.
- 2003 *Do Physicians Use Free Drug Samples to Increase Access for Need Patients?* AcademyHealth, Nashville, TN.
- 2003 *Trends and Future Expectations for Employer-Sponsored Prescription Coverage for New Retiree Medicare Beneficiaries.* AcademyHealth, Nashville, TN.
- 2004 *Impact of Antipsychotic Use on Antiparkinson Agents among Medicare Beneficiaries,* Annual Meeting, American Psychiatric Association, New York, NY.
- 2004 *Health Status and Daily Functioning as Predictors of Hospitalization in Patients Treated for Congestive Heart Failure.* American Society of Hypertension, New York, NY.
- 2004 *Evaluation of Nationally-mandated Drug Use Reviews to Improve Patient Safety in Nursing Homes: A Natural Experiment,* AcademyHealth, podium presentation, San Diego, CA.
- 2004 *Treatment Costs and Disease Burden of Patients with Paget's Disease,* ISPOR, Hamburg, Germany.

- 2004 *Use of Abusable Prescription Drugs by Community-Dwelling Elders*. American Public Health Association, Washington DC.
- 2005 *Disease Burden and Treatment Costs of Elderly Patients with Paget's Disease*, American Geriatrics Society, Orlando, FL.
- 2005 *Treatment Costs of Paget's Disease as a Measure of Morbidity*, National Association for the Relief of Paget's Disease, Oxford, UK.
- 2005 *Costs of Treating Patient's Disease in a Privately Insured Population*, Association of Bone and Mineral Research, Nashville, TN.
- 2006 *Adverse Drug Events Resulting from Patient Errors*. American Geriatrics Society, Chicago, IL.
- 2006 *Patient Cost-sharing and Persistence with Antihypertensive Drugs*. American Society of Hypertension, New York, NY.
- 2006 *Economic Impact of the Previous Year's Adherence with Bisphosphonates*. American College of Rheumatology, Boston, MA.
- 2007 *State-of-the Art and Ollie Randall Symposium: Evaluation of Medicare Part D in Nursing Homes*. Gerontological Society of America, podium presentation, San Francisco, CA.
- 2008 *Restrictive Drug Reimbursement Policies in Nursing Homes: Medicare Part D Exclusion of Benzodiazepines*. Gerontological Society of America, podium presentation, Washington, DC.
- 2009 *Effect of Medicare Part D on Use of Psychoactive Drugs in Nursing Homes*. Commonwealth Medicine Research Policy Forum, Boston
- 2010 *Out-of-Pocket Burden of Health Care Spending and the Adequacy of Medicare Part D*. American Society for Health Economists, Ithaca, NY.
- 2011 *Impact of Medicare Part D on Drug Utilization, Health Outcomes, and Medical Spending*. Invited research panel, AcademyHealth, Seattle.